Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Otolaryngol Head Neck Surg ; 127(7): 775-9, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11448348

ABSTRACT

OBJECTIVE: To investigate the safety and efficacy of alloantigen plasmid DNA therapy in patients with advanced head and neck squamous cell carcinoma using Allovectin-7 (Vical Inc, San Diego, Calif), a DNA/lipid complex designed to express the class I major histocompatibility complex antigen HLA-B7. DESIGN: Multi-institutional prospective trial. SETTING: Academic medical setting. PATIENTS: A total of 69 patients were enrolled in 3 sequential clinical trials: a single-center phase 1 trial and 2 multicenter phase 2 trials. Eligibility criteria included unresectable squamous cell carcinoma that failed conventional therapy, Karnofsky performance status score of 70 or greater, and no concurrent anticancer or immunosuppressive therapies. INTERVENTION: Patients received 2 biweekly intratumoral injections of 10 microg (phase 1 and first phase 2 trials) or 100 microg (second phase 2 trial) of Allovectin-7 followed by 4 weeks of observation. Patients with stable or responding disease after the observation period were given a second treatment cycle identical to the first. MAIN OUTCOME MEASURES: Patients were assessed for toxic effects, and tumor size was measured after cycles 1 (at 6 weeks) and 2 (at 16 weeks). RESULTS: Allovectin-7 treatment was well tolerated, with no grade 3 or 4 drug-related toxic effects. Of 69 patients treated, 23 (33%) had stable disease or a partial response after the first cycle of treatment and proceeded to the second cycle. After the second cycle, 6 patients had stable disease, 4 had a partial response, and 1 had a complete response. Responses persisted for 21 to 106 weeks. CONCLUSIONS: Intratumoral plasmid DNA immunotherapy for head and neck cancer with Allovectin-7 is safe, and further investigations are planned in patients with less advanced disease, where it could potentially improve patient survival and reduce the need for radical high-morbidity treatments.


Subject(s)
Carcinoma, Squamous Cell/therapy , DNA/administration & dosage , Gene Transfer Techniques , HLA-B7 Antigen/therapeutic use , Immunotherapy , Lipids/therapeutic use , Otorhinolaryngologic Neoplasms/therapy , Plasmids/genetics , Plasmids/therapeutic use , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , DNA/adverse effects , DNA, Recombinant , Disease Progression , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , HLA-B7 Antigen/adverse effects , Humans , Injections, Intralesional , Lipids/adverse effects , Male , Middle Aged , Neoplasm Staging , Otorhinolaryngologic Neoplasms/mortality , Otorhinolaryngologic Neoplasms/pathology , Plasmids/adverse effects , Survival Rate
2.
Arch Otolaryngol Head Neck Surg ; 124(10): 1097-104, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9776187

ABSTRACT

OBJECTIVE: To determine the safety and efficacy of an immunogenic gene therapy using a drug designed to produce expression of a foreign class I major histocompatibility complex protein in patients with head and neck cancer. DESIGN: Phase 1 prospective clinical trial. SETTING: Academic medical setting. PATIENTS: Nine patients with advanced head and neck squamous cell carcinoma who had failed conventional therapy and did not express HLA-B7, a class I major histocompatibility complex protein. INTERVENTION: Patients were treated with Allovectin-7 (Vical Inc, San Diego, Calif) by direct intratumoral injection. Allovectin-7 contains a plasmid complementary DNA complexed with a cationic lipid, which results in expression of HLA-B7. MAIN OUTCOME MEASURES: Patients were assessed for any toxic effects and for any change in tumor volume. Biopsy specimens obtained before and after therapy were evaluated by immunohistochemistry to detect HLA-B7 expression and with the terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) assay to detect any induction of apoptosis. RESULTS: There were no toxic effects of the gene therapy. In 4 of these 9 patients there was a partial response to treatment, evidenced by a gradual reduction in tumor size. One patient has remained alive for more than 17 months since commencing treatment, with no clinical evidence of disease but with persistent histological evidence of cancer. Analysis of the biopsy specimens from 2 of the patients who responded to therapy demonstrated HLA-B7 expression. The TUNEL assay demonstrated extensive apoptosis in both of these patients, suggesting that this may be the mechanism of tumor reduction. CONCLUSIONS: These data demonstrate the potential efficacy and lack of toxicity of this form of alloantigen gene therapy. A multi-institutional study has been initiated to expand on these findings.


Subject(s)
Carcinoma, Squamous Cell/therapy , DNA , Genetic Therapy/methods , HLA-B7 Antigen/therapeutic use , Head and Neck Neoplasms/therapy , Lipids/therapeutic use , Plasmids/therapeutic use , Adult , Aged , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/mortality , Combined Modality Therapy , DNA, Recombinant , Female , Genetic Therapy/adverse effects , HLA-B7 Antigen/adverse effects , Head and Neck Neoplasms/immunology , Head and Neck Neoplasms/mortality , Histocompatibility Testing , Humans , Immunohistochemistry , Lipids/adverse effects , Male , Middle Aged , Patient Selection , Plasmids/adverse effects , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...